Literature DB >> 30259340

Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients?

Franco Piovella1, Diana Irina Iosub2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30259340     DOI: 10.1007/s11739-018-1953-4

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  17 in total

1.  Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

Authors:  Samuel Z Goldhaber; Alain Leizorovicz; Ajay K Kakkar; Sylvia K Haas; Geno Merli; Robert M Knabb; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment.

Authors:  Alexander T Cohen; Robert Harrington; Samuel Z Goldhaber; Russell Hull; C M Gibson; Adrian F Hernandez; Alex Gold
Journal:  Am Heart J       Date:  2014-09-19       Impact factor: 4.749

4.  Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.

Authors:  Russell D Hull; Sebastian M Schellong; Victor F Tapson; Manuel Monreal; Meyer-Michel Samama; Philippe Nicol; Eric Vicaut; Alexander G G Turpie; Roger D Yusen
Journal:  Ann Intern Med       Date:  2010-07-06       Impact factor: 25.391

5.  A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score.

Authors:  S Barbar; F Noventa; V Rossetto; A Ferrari; B Brandolin; M Perlati; E De Bon; D Tormene; A Pagnan; P Prandoni
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

6.  Predictive and associative models to identify hospitalized medical patients at risk for VTE.

Authors:  Alex C Spyropoulos; Frederick A Anderson; Gordon FitzGerald; Herve Decousus; Mario Pini; Beng H Chong; Rainer B Zotz; Jean-François Bergmann; Victor Tapson; James B Froehlich; Manuel Monreal; Geno J Merli; Ricardo Pavanello; Alexander G G Turpie; Mashio Nakamura; Franco Piovella; Ajay K Kakkar; Frederick A Spencer
Journal:  Chest       Date:  2011-03-24       Impact factor: 9.410

7.  D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.

Authors:  A T Cohen; T E Spiro; A C Spyropoulos; Y H Desanctis; M Homering; H R Büller; L Haskell; D Hu; R Hull; A Mebazaa; G Merli; S Schellong; V F Tapson; P Burton
Journal:  J Thromb Haemost       Date:  2014-04       Impact factor: 5.824

8.  Venous thromboembolism in the outpatient setting.

Authors:  Frederick A Spencer; Darleen Lessard; Cathy Emery; George Reed; Robert J Goldberg
Journal:  Arch Intern Med       Date:  2007-07-23

9.  Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population.

Authors:  Charles E Mahan; Maxine D Fisher; Roger M Mills; Larry E Fields; Judith J Stephenson; An-Chen Fu; Alex C Spyropoulos
Journal:  Thromb Res       Date:  2013-08-28       Impact factor: 3.944

10.  Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.

Authors:  Alexander T Cohen; Robert A Harrington; Samuel Z Goldhaber; Russell D Hull; Brian L Wiens; Alex Gold; Adrian F Hernandez; C Michael Gibson
Journal:  N Engl J Med       Date:  2016-05-27       Impact factor: 91.245

View more
  1 in total

1.  A focus on direct oral anticoagulants: "old" and possible new indications and efforts for a better clinical management.

Authors:  Domenico Prisco
Journal:  Intern Emerg Med       Date:  2018-09-21       Impact factor: 3.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.